Skip to main content
IL DONG PHARMACEUTICAL CO., LTD. logo

IL DONG PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 249420 ISIN · KR7249420001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-05-29 Governance Information
Country KR South Korea
Listing KO 249420

About IL DONG PHARMACEUTICAL CO., LTD.

https://mobile.ildong.com/eng/main/main…

IL DONG PHARMACEUTICAL CO., LTD. is a pharmaceutical company engaged in the research, development, manufacturing, and commercialization of a broad range of healthcare products. The company's portfolio encompasses ethical drugs, over-the-counter (OTC) medications, active pharmaceutical ingredients (APIs), and health functional foods. Key therapeutic areas of focus include metabolic disorders, gastrointestinal diseases, degenerative diseases, oncology, and cardiovascular conditions. Its robust research and development pipeline features promising drug candidates such as an oral GLP-1 receptor agonist for diabetes and obesity, a P-CAB class treatment for peptic ulcers, and a first-in-class CXCR7 agonist for fibrotic diseases. Utilizing its GMP-certified facilities, the company also offers contract manufacturing (CMO) services, with specialized capabilities in antibiotics and oncology drugs, while actively pursuing global expansion through strategic partnerships and licensing.

Recent filings

Filing Released Lang Actions
기업지배구조보고서공시
Governance Information Classification · 91% confidence The document is the company’s Corporate Governance Report (“기업지배구조보고서 신고서”) covering governance policies, board composition, key governance indicators, shareholder meeting procedures, and detailed voting results. It is a full governance disclosure, not merely an AGM presentation or a brief announcement. This matches the definition of Governance Information (CGR).
2026-05-29 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled 분기보고서 (Quarterly Report) covering the 11th fiscal period from January 1, 2026 to March 31, 2026. It contains a full set of substantive financial and operational data for the quarter, including sales, production metrics, risk management policies, and detailed tables of assets, liabilities, and equity changes. This matches the definition for an Interim / Quarterly Report (IR), not merely an announcement or a summary. Q1 2026
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 92% confidence The document is a formal “공정공시” preliminary (잠정) operating performance announcement for Q1 2026 under K-IFRS, providing key financial highlights (revenue, operating profit, net income, etc.) versus prior periods. It is not a full interim report with detailed statements and analysis, but an initial earnings disclosure. This corresponds to an Earnings Release (ER). Q1 2026
2026-05-13 Korean
결산실적공시예고(안내공시)
Report Publication Announcement Classification · 85% confidence The document is titled a ‘결산실적공시 예고(안내공시)’ (pre-announcement of financial results) and contains no actual financial data—only the scheduled date when the results will be publicly posted on the company’s IR site. It is purely an announcement of the upcoming report timing, fitting the definition of a Report Publication Announcement (RPA).
2026-05-11 Korean
주주명부폐쇄기간또는기준일설정
Declaration of Voting Results & Voting Rights Announcements Classification · 80% confidence The document is a brief announcement of the shareholder record date (기준일) and register closure period for determining shareholders with voting rights regarding a small‐scale merger. This falls under “Declaration of Voting Results & Voting Rights Announcements”, as it officially sets the date for voting rights. It is not the full meeting materials or minutes, but specifically a voting rights announcement.
2026-04-14 Korean
주요사항보고서(회사합병결정)
M&A Activity Classification · 91% confidence The document is titled “주요사항보고서(회사합병 결정)” and contains a detailed description of the decision to merge a wholly-owned subsidiary into the parent company, including merger method, ratio, schedule, financial impacts, related party transactions and legal terms. It is a full corporate action filing regarding an M&A transaction, not an earnings release or an annual/quarterly report. Therefore it corresponds to the M&A Activity category (Code: TAR).
2026-04-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.